Taken together, the tumor proliferation marker MKI67 and a new prognosis marker GRHL2 collaborate with several mesenchymal markers as a “poor-prognosis” gene-set, while two epithelial markers perform as a “good-prognosis” gene-set. This evidence concerns the gene GRHL2 and neoplasm.